DIRS.INFO The most relevant business & tech news

Top picks for Cyber Monday laptop salesDeal icon An icon in the shape of a lightning bolt. $1,999.99 from Amazon Originally $2,499.00 Save 20%Deal icon An icon in the shape of a lightning bolt. $1,049.00 from Amazon Originally $1,199.00 Save 13%Deal icon An icon in the shape of a lightning bolt. $1,599.00 from Best Buy Originally $1,999.00 Save 20%Deal icon An icon in the shape of a lightning bolt. $2,099.99 from Best Buy Originally $2,799.99 Save 25%Deal icon An icon in the shape of a lightning bolt.

Among them is Best Buy: Its holiday sale began on October 24 and we expect even better deals to pop up today. It's now available on clearance from Best Buy, making it even more affordable to buy than ever. $739.00 from Best Buy Originally $799.00 Save 8%Best Buy Cyber Monday 2022: What to expectThough Best Buy's holiday sale already kicked off a while ago, the best deals are cropping up today on Cyber Monday. Best Buy has stated that its sale has already begun since October 24, but we expect the best deals to show up on Cyber Monday. Best Buy store hours differ by location, so you'll need to check your local store's Cyber Monday hours.

Best Cyber Monday gaming PC gaming dealsDeal icon An icon in the shape of a lightning bolt. Great Price ASUS ROG Strix G15 Gaming Desktop PC ROG Strix is ASUS' premiere PC gaming brand, and this prebuilt PC is a great example of the quality that name brings. Best Cyber Monday PC gaming monitor dealsDeal icon An icon in the shape of a lightning bolt. $139.99 from Best Buy Originally $249.99 Save 44%Best Cyber Monday PC gaming graphic card dealsDeal icon An icon in the shape of a lightning bolt. Best Cyber Monday PC gaming SSD dealsDeal icon An icon in the shape of a lightning bolt.

And during Black Friday, it's more than $1000 off — the absolute best gaming laptop deal we've seen so far. Deal Alienware m15 Ryzen™ Edition R5 Gaming Laptop Alienware gaming laptops are notoriously expensive. Great Price ASUS ROG Zephyrus G14 Gaming Laptop The ROG Zephyrus G14 has the specs of a high-end gaming laptop for an affordable price. The best gaming laptops have top-of-the-line GPUs built into them, which is what lets them run new games with the best visuals possible. Where can you find the best Black Friday gaming laptop deals?

☆ Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
▼ + stars: | 2022-11-16 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.

☆ U.S. FDA authorizes Roche's monkeypox test
▼ + stars: | 2022-11-15 | by ( ) www.reuters.com time to read: 1 min

Nov 15 (Reuters) - The U.S. Food and Drug Administration on Tuesday issued an emergency use authorization to Roche's (ROG.S) monkeypox test. Reporting by Leroy Leo in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.

The comments follow a softer-than-expected inflation report last week, which had buoyed hopes that the Fed could scale back its hefty interest rate hikes and helped drive a euphoric market rally. The S&P 500 in the previous session logged its biggest weekly percentage gain in about five months, while the tech-heavy Nasdaq (.IXIC) notched its best week since March. "The market is expecting the Fed to continue its hawkish rhetoric on rates. ET, the S&P 500 (.SPX) was down 17.25 points, or 0.43%, at 3,975.68, and the Nasdaq Composite (.IXIC) was down 115.13 points, or 1.02%, at 11,208.20. The S&P 500 information technology sector (.SPLRCT) was down 1.2% and among the leading sectoral decliners on the benchmark index.

The comments follow a softer-than-expected inflation report last week, which had buoyed hopes that price pressures were easing and the Fed could scale back its hefty interest rate hikes. "The market is expecting the Fed to continue its hawkish rhetoric on rates," said Peter Cardillo, chief market economist at Spartan Capital Securities. Once they (Fed) raise rates at 50 (bps), there's a possibility that they might indicate slower rates." Traders now expect the Fed to hike interest rates in December by a half point, and expect terminal rate in the range of 4.75%-5.0% next year. ET, Dow e-minis were down 50 points, or 0.15%, S&P 500 e-minis were down 11.5 points, or 0.29%, and Nasdaq 100 e-minis were down 62 points, or 0.52%.

☆ Roche's Alzheimer's drug fails to meet goal in long awaited trial
▼ + stars: | 2022-11-14 | by ( Ludwig Burger | ) www.reuters.com time to read: +4 min

Nov 14 (Reuters) - Roche said (ROG.S) its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen (BIIB.O) and Eisai (4523.T). Within each study, volunteers were randomly assigned to receive either the injectable antibody drug gantenerumab or a placebo. The quest to develop an Alzheimer's drug, targeting beta-amyloid or other molecules, has been beset by a long list of study failures. But rival Biogen in September scored a surprise trial success with an experimental Alzheimer's drug that it developed with Eisai, rebuilding confidence among industry executives and researchers in the beta-amyloid approach. Schwan earlier this year sought to curb expectations for the Graduate trials but the head of Roche's pharma unit last month acknowledged that Biogen's success with lecanemab had reignited hopes.

☆ Roche reminds investors big drug bets have risks
▼ + stars: | 2022-11-14 | by ( ) www.reuters.com time to read: +2 min

LONDON, Nov 14 (Reuters Breakingviews) - Shareholders in Swiss drug giant Roche (ROG.S) are learning the downside of making big bets on new drugs. Credit Suisse analysts reckoned the drug could eventually generate around $10 billion of sales. If shareholders had valued that revenue at the same 4 times multiple at which Roche currently trades, the drug could have added nearly $40 billion of value to the company. That suggests investors were attaching a less than one-in-three chance of the drug being a success. Roche investors should brace for more big bets.

☆ What Cramer is watching Tuesday — possible GOP gains, Nvidia bounces, Kohl's CEO out
▼ + stars: | 2022-11-08 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

Lyft (LYFT) downgraded to in line from outperform (hold from buy) at Evercore, one of many negative Wall Street notes. Price target cuts: Credit Suisse to $122 per share from $137 and Baird to $120 from $140. Raymond James cuts price target on Palantir (PLTR) to $15 per share from $20 but has strong buy. Meanwhile, multiple price cuts on Celanese. Mizuho cut price target on cloud data provider Snowflake (SNOW) to $185 per share from $225 but keeps buy rating.

Qualcomm (QCOM.O) ended its $44 billion purchase of Dutch peer NXP Semiconductors NV in 2018 after failing to secure regulatory approval. read moreChina's regulators have declined to comment on the DuPont deal and have not provided a reason for the delay in reviewing it. One merger arbitrage fund investor, who declined to be named, said deals involving Chinese approval will be closely watched in the aftermath of the scrapped DuPont-Rogers deal. Shares of some U.S. companies with a significant footprint in China that are waiting to complete deals dropped on Wednesday as a result. Some investors cautioned, however, that the collapse of these deals hinges not just on whether Chinese regulators will withhold clearance but also on whether the acquirers are committed to the transactions.

☆ DuPont scraps $5.2 bln Rogers buyout due to China hurdles
▼ + stars: | 2022-11-02 | by ( ) www.reuters.com time to read: +2 min

DuPont said the termination of the deal was agreed with Rogers as they have been unable to obtain timely clearance from all the required regulators. Shares of engineering materials maker Rogers plunged 43% in extended trading on Tuesday, while those of DuPont rose about 6%. The collapsed Rogers deal is the most prominent global acquisition to be called off in four years due to Chinese regulatory hurdles. In 2018, Qualcomm Inc (QCOM.O) walked away from a $44 billion deal to buy NXP Semiconductors (NXPI.O) after failing to secure Chinese regulatory approval amid China-U.S. trade tensions. DuPont added it would pay Rogers a termination fee of $162.5 million.

☆ Stocks making the biggest moves premarket: CVS, Estee lauder, Canada Goose and others
▼ + stars: | 2022-11-02 | by ( Peter Schacknow | ) www.cnbc.com time to read: +3 min

Check out the companies making headlines before the bell:CVS (CVS) – CVS gained 1.9% in the premarket after reporting better-than-expected revenue and profit for its latest quarter. Estee Lauder reported better-than-expected earnings for its latest quarter. Canada Goose (GOOS) – The outerwear company cut its full-year revenue forecast, prompting a 2.4% premarket drop in its shares. Livent (LTHM) – Livent lost 4.7% in premarket trading after the lithium producer cut its full-year sales and profit forecast. Mondelez (MDLZ) – Mondelez gained 3.3% in the premarket after the maker of Oreos, Sour Patch Kids, and other snacks raised its full-year outlook.

☆ What Cramer is watching Wednesday — Fed day, AMD signs of life, China hits Estee Lauder
▼ + stars: | 2022-11-02 | by ( Jim Cramer | ) www.cnbc.com time to read: +5 min

While missing lowered expectations in the third quarter, Club holding AMD did see a year-over-year revenue growth. Club holding Estee Lauder (EL) beats on fiscal first-quarter earnings and matches on revenue. Club holding Devon Energy (DVN): Very strong quarter . Club holding Humana (HUM) sees membership growth. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Organizations: & $

☆ DuPont takes welcome M&A break
▼ + stars: | 2022-11-02 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, Nov 2 (Reuters Breakingviews) - The seemingly eternal makeover at DuPont de Nemours (DD.N) has been forced into a welcome pause. The chemicals giant just scrapped its $5.2 billion acquisition of engineered materials manufacturer Rogers (ROG.N) after failing to secure clearance from Chinese authorities. Under boss Ed Breen, DuPont has undertaken a series of mergers and spinoffs. To pay for the deal, DuPont sold most of its so-called Mobility & Materials division to Celanese (CE.N) for $11 billion. The problem is that DuPont ditched old businesses at lower valuation multiples to fund purchases at much higher ones.

☆ DuPont pulls the plug on $5.2 bln buyout of Rogers on clearance issues
▼ + stars: | 2022-11-01 | by ( Yousef Saba | ) www.reuters.com time to read: 1 min

Nov 1 (Reuters) - Chemicals maker DuPont De Nemours Inc (DD.N) said on Tuesday it was terminating its $5.2 billion buyout of Rogers Corp (ROG.N) as they were unable to obtain timely regulatory clearances for the deal. Rogers shares plunged 43% in extended trading, while those of DuPont rose about 6%. DuPont added it would pay Rogers a termination fee of $162.5 million. The companies said in September that they had received all regulatory approvals for the deal except from China. Reporting by Ruhi Soni in Bengaluru; Editing by Anil D'SilvaOur Standards: The Thomson Reuters Trust Principles.

Oct 25 (Reuters) - Biogen Inc (BIIB.O) on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd (4523.T) would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co (LLY.N) and Roche (ROG.S). The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month. "The data needs to be seen from the other anti-amyloid therapies before we decide what is going to be meaningful," said Biogen interim research chief Priya Singhal. Its costs were about halved as the company significantly cut back on commercial infrastructure around the launch of Aduhelm, its previous Alzheimer's drug that has sputtered amid controversy over efficacy and lack of coverage by health insurers. read moreInvestors have been pinning hopes on the Alzheimer's drug as cheaper generics of Biogen's multiple sclerosis treatment Tecfidera have entered the market, hurting sales.

☆ European shares at near two-week high amid UK fiscal plan optimism
▼ + stars: | 2022-10-18 | by ( Amruta Khandekar | ) www.reuters.com time to read: +2 min

The region-wide STOXX 600 index (.STOXX) was up 0.9% by 0826 GMT, hitting a near two-week high, as investors snapped up beaten-down tech (.SX8P) and bank (.SX7P) stocks. Shares of chipmakers, including ASML Holdings (ASML.AS) and BE Semiconductor (BESI.AS), rose between 0.9% and 4% amid a risk-on sentiment in markets. "If you make that U-turn too extreme and basically embark on a trajectory of significant fiscal tightening, that could also do more more harm. Investors also took comfort from a recent pullback in natural gas prices in Europe, which is battling an energy crisis amid growing risks of a recession. Rio Tinto (RIO.L) slipped 0.7% after it projected annual iron ore shipments at the lower end of its forecast amid weak global demand.

☆ Roche sales decline more than expected as COVID products slide
▼ + stars: | 2022-10-18 | by ( Ludwig Burger | Nancy Lapid | ) www.reuters.com time to read: +2 min

Third-quarter revenue slipped to 14.74 billion Swiss francs ($14.84 billion), below market expectations of about 15.5 billion francs. Its bestseller Ocrevus gained 16% in sales to 1.52 billion francs during the quarter, while Hemlibra jumped 23% to 952 million francs, both excluding the effect of currency swings. However, analysts at brokerage Jefferies said sales gains in Hemlibra and cancer immunotherapy Tecentriq fell short of market expectations. It also reiterated that the percentage gain in core earnings per share would be in the "low- to mid-single digit" range. Roche repeated that keenly awaited trial data on experimental Alzheimer's drug gantenerumab was due to be published at the end of November.

☆ EXCLUSIVE Schlumberger faces employee backlash in Russia over cooperation on draft
▼ + stars: | 2022-10-14 | by ( Liz Hampton | ) www.reuters.com time to read: +5 min

Human rights groups are watching how the company responds to the concerns. Schlumberger suspended new investments and technology deployment in Russia, but unlike some of its peers and customers, decided to remain. Schlumberger leaves decision-making on Russia employment policies to local managers, the U.S.-based spokesperson said. The Business & Human Rights Resource Centre requested information from Schlumberger and other non-Russian companies with operations in the country on their handling of the mobilization. Schlumberger rivals Baker Hughes (BKR.O) and Halliburton (HAL.N) are selling or have sold their oilfield services units in Russia.

The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures. Biogen's stock surged 46.6% to $290.99 in premarket trading, putting it on track to add over $13.5 billion in market capitalization. BMO analyst Evan Seigerman called the data an "unequivocal win" for Biogen and Alzheimer's patients. The latest trial boost for Biogen and Eisai's lecanemab has raised hope for success in trials testing Roche's gantenerumab and Lilly's donanemab. Shares of smaller Alzheimer's drug developers also rose in premarket U.S. trading.

☆ Analysis: Alzheimer's drug trial breakthrough boost for Roche, Eli Lilly
▼ + stars: | 2022-09-28 | by ( Natalie Grover | ) www.reuters.com time to read: +5 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Nearly all Alzheimer's drugs, including those targeting amyloid, have stumbled in trials. Late-stage data on gantenerumab is expected by the fourth quarter, Roche said in a statement, saying it was encouraged by the lecanemab data. Results of a key late-stage trial testing the drug are anticipated by mid-2023. AMYLOID HYPOTHESISSome researchers, including Frederiksen, are cautiously optimistic about the impact the Biogen, Eisai data has on the likelihood of success for the other two drugs in development.

Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co , which is also developing an Alzheimer's drug, were up 6.7% in after hours trade. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost. Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's (ROG.S) gantenerumab and Eli Lilly's donanemab.

Search resuls for: "ROG"

25 mentions found